|
|
|
TSRO - TESARO, Inc.
TESARO, Inc. (TSRO) is a biopharmaceutical company that is focused on developing and commercializing cancer treatments. The company is headquartered in Waltham, Massachusetts, and was founded in 2010.
TESARO's lead product is called Zejula (niraparib), which is an oral, once-daily PARP inhibitor that is used to treat ovarian cancer. The drug was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and has since been approved for use in Europe and other markets. TESARO is also working on developing other cancer treatments, including immunotherapies and antibody-drug conjugates.
In addition to its focus on cancer treatments, TESARO is also committed to developing its commercial capabilities and expanding its global presence. The company has partnerships with several major pharmaceutical companies, including Janssen Biotech and Merck, and has operations in the United States, Europe, and Asia.
TESARO's stock is traded on the NASDAQ Global Select Market under the ticker symbol "TSRO."
|
|
|
|
|
